RxDoctor Payments Data

Arwen Bassler, MD

Family Medicine · Clymer, PANPI 1669484267

Payments from drug & device makers

$463in general payments, 2019–2025

Across 31 payments — averaging $14.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$58
  • Lilly USA, LLC$51
  • Amarin Pharma, Inc.$49
  • Novo Nordisk$46
  • Amgen$44
  • Johnson & Johnson$41
  • plus $175 from 7 others

What the payments were for

  • Food & beverage$463100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer4$58
Lilly USA, LLC3$51
Amarin Pharma, Inc.3$49
Novo Nordisk3$46
Amgen3$44
Johnson & Johnson3$41
Boehringer Ingelheim3$41
Abbott2$39
Sanofi Pasteur Inc.2$26
Merck2$24
Dexcom, Inc.1$18
GSK1$15
Nalpropion Pharmaceuticals LLC1$11

How this compares

$463 in reported general payments places this provider in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$49,320
Medicare patients
145
Services billed
541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$74,078
JardianceEmpagliflozin70$70,119
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$48,773
TrulicityDulaglutide31$43,248
RybelsusSemaglutide18$42,096
MounjaroTirzepatide39$38,905
OzempicSemaglutide34$37,778
TradjentaLinagliptin25$23,765
Breo ElliptaFluticasone/Vilanterol26$11,219
ShingrixVaricella-Zoster Ge/As01b/Pf45$10,106
LinzessLinaclotide14$8,406
XareltoRivaroxaban14$7,942
Atorvastatin Calcium341$5,491
Levothyroxine Sodium243$3,213
SynthroidLevothyroxine Sodium47$3,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$41$93,88495 claims
Lilly USA, LLCTrulicity, Mounjaro$51$82,15370 claims
Novo NordiskRybelsus, Ozempic$46$79,87452 claims
PfizerEliquis$58$74,07870 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$15$70,098117 claims
Johnson & JohnsonXarelto$41$7,94214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Clymer

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →